{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-060020","form_type":"8-K","ticker":"KZR","cik":"0001645666","company_name":"Kezar Life Sciences, Inc.","filed_at":"2021-12-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.470115+00:00","generated_at":"2026-06-28T02:04:50.707384+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Kezar Life Sciences appoints Courtney Wallace to board; director Jason Dinges resigns","bullets":["Jason Dinges, Ph.D., resigned from the board effective Dec 9, 2021; departure not due to disagreement.","Courtney Wallace appointed as Class I director, serving until 2022 annual meeting or successor.","Wallace receives annual cash compensation of $35,000 plus initial option for 52,000 shares vesting monthly over 3 years."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-060020","json":"https://secwatch.observer/filing/0001564590-21-060020.json","markdown":"https://secwatch.observer/filing/0001564590-21-060020.md","text":"https://secwatch.observer/filing/0001564590-21-060020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645666/000156459021060020/0001564590-21-060020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645666/000156459021060020/kzr-8k_20211209.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T02:04:50.707384+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"619018c8cc","claim":"Jason Dinges resigned as Director at Kezar Life Sciences, Inc..","evidence_excerpt":"Effective December 9, 2021, Jason Dinges, Ph.D., resigned from the Board of Directors (the “Board”) of Kezar Life Sciences, Inc. (the “Company”) and from his position as a member of the Nominating and Corporate Governance Committee of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645666/000156459021060020/0001564590-21-060020-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"84d125bd98","claim":"Courtney Wallace was appointed as Director at Kezar Life Sciences, Inc..","evidence_excerpt":"Effective December 9, 2021, the Board appointed Courtney Wallace to the Board as a Class I Director, to serve until the Company’s 2022 annual meeting of stockholders and until her successor is duly elected and qualified, or her earlier resignation or removal.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645666/000156459021060020/0001564590-21-060020-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}